Cel-Sci

Update in progress

CVM (NYSE American)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

CEL-SCI Corporation is a clinical-stage biotechnology company focused on cancer and immune-related diseases in the United States. Its lead immunotherapy, Multikine, has completed Phase III trials for certain head and neck cancers. It also develops LEAPS, a patented T-cell modulation platform to stimulate the immune system against infections, autoimmune conditions, allergies, transplantation rejection, and cancer, with potential rheumatoid arthritis use. LEAP candidates CEL-2000, CEL-4000, and CEL-5000 are in preclinical development. The company has a strategic partnership with Saudi Arabian Pharmaceutical Company for Multikine in head and neck cancer. Founded in 1983, based in Vienna, Virginia.

Company score

Sentiment: 0.33; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.22; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.12; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.09; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.21; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive